Linden Thomas Advisory Services LLC Acquires 489 Shares of Vericel Co. (NASDAQ:VCEL)

Linden Thomas Advisory Services LLC increased its holdings in Vericel Co. (NASDAQ:VCEL) by 1.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 43,781 shares of the biotechnology company’s stock after acquiring an additional 489 shares during the quarter. Linden Thomas Advisory Services LLC owned about 0.09% of Vericel worth $2,404,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in VCEL. Mirae Asset Global Investments Co. Ltd. grew its holdings in Vericel by 22.2% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,773 shares of the biotechnology company’s stock worth $77,000 after purchasing an additional 322 shares during the period. Farther Finance Advisors LLC boosted its position in shares of Vericel by 48.1% in the 3rd quarter. Farther Finance Advisors LLC now owns 1,247 shares of the biotechnology company’s stock worth $53,000 after purchasing an additional 405 shares in the last quarter. PFG Investments LLC grew its stake in shares of Vericel by 8.0% in the 3rd quarter. PFG Investments LLC now owns 7,400 shares of the biotechnology company’s stock worth $313,000 after buying an additional 550 shares during the last quarter. International Assets Investment Management LLC grew its stake in shares of Vericel by 4,126.7% in the 3rd quarter. International Assets Investment Management LLC now owns 634 shares of the biotechnology company’s stock worth $27,000 after buying an additional 619 shares during the last quarter. Finally, Advisors Asset Management Inc. increased its position in Vericel by 4.0% during the 3rd quarter. Advisors Asset Management Inc. now owns 16,890 shares of the biotechnology company’s stock valued at $714,000 after buying an additional 644 shares in the last quarter.

Insider Buying and Selling

In other Vericel news, insider Jonathan Mark Hopper sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $58.72, for a total transaction of $587,200.00. Following the completion of the sale, the insider now directly owns 58,371 shares of the company’s stock, valued at approximately $3,427,545.12. This represents a 14.63 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Robert L. Md Zerbe sold 2,500 shares of Vericel stock in a transaction on Friday, November 22nd. The stock was sold at an average price of $60.00, for a total transaction of $150,000.00. Following the transaction, the director now owns 26,595 shares in the company, valued at $1,595,700. This represents a 8.59 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 15,100 shares of company stock valued at $889,872 over the last 90 days. Company insiders own 5.20% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have commented on the company. StockNews.com raised Vericel from a “sell” rating to a “hold” rating in a report on Tuesday, December 24th. HC Wainwright reissued a “buy” rating and set a $60.00 price objective on shares of Vericel in a research report on Wednesday, January 15th. Truist Financial raised their price objective on shares of Vericel from $61.00 to $67.00 and gave the company a “buy” rating in a research note on Wednesday, December 18th. Canaccord Genuity Group reiterated a “buy” rating and issued a $60.00 target price on shares of Vericel in a research note on Tuesday, November 19th. Finally, BTIG Research raised their price target on shares of Vericel from $56.00 to $66.00 and gave the company a “buy” rating in a research report on Tuesday, November 26th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $62.14.

Vericel Stock Up 0.0 %

Shares of VCEL stock opened at $57.43 on Friday. The company has a 50 day moving average price of $57.30 and a 200-day moving average price of $50.40. Vericel Co. has a 52 week low of $39.12 and a 52 week high of $61.49. The firm has a market capitalization of $2.83 billion, a PE ratio of 957.33 and a beta of 1.72.

Vericel (NASDAQ:VCEL) last issued its earnings results on Thursday, November 7th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.05) by $0.03. The company had revenue of $57.91 million for the quarter, compared to analysts’ expectations of $55.32 million. Vericel had a net margin of 1.56% and a return on equity of 1.48%. Analysts anticipate that Vericel Co. will post 0.12 earnings per share for the current year.

Vericel Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.